Drug Profile
AN 10
Alternative Names: NovahemeLatest Information Update: 30 Nov 1997
Price :
$50
*
At a glance
- Originator Bar-Ilan University
- Developer Discovery Laboratories
- Class Antianaemics
- Mechanism of Action Fetal haemoglobin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Sickle cell anaemia; Thalassaemia
Most Recent Events
- 30 Nov 1997 Discontinued-Preclinical for Sickle cell anaemia in USA (Unknown route)
- 30 Nov 1997 Discontinued-Preclinical for Thalassaemia in USA (Unknown route)
- 20 Feb 1997 New profile